You are here

Coronary Intervention & Surgery

 - PCI

One year after patients underwent PCIs, approximately 1 percent had gastrointestinal bleeding, which was associated with an increased risk for all-cause mortality and the composite of death, MI or stroke.

 - children

Children who remained unconscious after out-of-hospital cardiac arrest had similar survival rates and cognitive functioning if they received therapeutic hypothermia or therapeutic normothermia, according to a randomized trial.

 - Synergy stent image circle

An everolimus-eluting stent with a bioresorbable coating held its own clinically against a durable polymer drug-eluting stent in the pivotal EVOLVE II trial, findings that may be used to determine regulatory approval of the bioresorbable device.

 - CABG Surgery

Patients with type 1 diabetes had double the risk of death after undergoing CABG compared with a group that did not have diabetes, according to an observational, nationwide population-based cohort study.

 - Green Radiation Symbol

Interventional cardiologists and nurses worry about cardiovascular disease developing in their patients. A study that looked at long-term radiation exposure to cath lab operators and staff may prompt them to add themselves to that list.


More Stories

Survey: Orthopedic injuries plague half of operators

Almost half of operators who responded to a survey on occupational health hazards in the cath lab reported they experienced at least one orthopedic injury, and more than one in 20 limited their case load because of radiation exposure.

Statement clarifies use of heart pumps in high-risk patients

Cardiologists trying to navigate the proper course of care for cardiac patients who might benefit from percutaneous mechanical circulatory support received a helping hand in the form of a consensus statement published online April 7. The document provides a roadmap for physicians until there is sufficient high-level evidence to inform guidelines.

Limb function, sensation not impinged by radial artery access

Chalk another one up for transradial access. According to results published online March 26, patients undergoing catheterization via the radial artery had no significant change to limb function and sensation, assessed by cold intolerance, was not adversely impacted.

Benefit of percutaneous heart pumps murky despite skyrocketing use

The use of percutaneous ventricular assist devices (PVADs) has grown by leaps and bounds in recent years, but a study published online March 30 in JAMA Internal Medicine casts doubt on their overall benefit, given the high costs and mortality rates.

Following STEMI PCI, discharge after 48 hours as safe as 3 to 4 days

Short hospital stays following PCI may be safe for older patients with STEMI. However, researchers caution stays of less than 48 hours may increase risk for 30-day mortality and major adverse cardiac events.

SCAI keynotes to emphasize tech, big data and research needs

The Society for Cardiovascular Angiography and Interventions’ (SCAI) 2015 convention will kick off May 6 with a session on state-of-the-art technologies, which will include keynote lectures by Christian Assad-Kottner, MD, of El Camino Hospital in Mountain View, Calif., and Peter J. Fitzgerald, MD, of Stanford University in California.

ACC.15: Upcoming PCI AUC take into account past criticisms

Acknowledging there was room for improvement, the authors of PCI appropriate use criteria (AUC) have applied lessons from the last set of guidelines in a revision scheduled for publication this year, a member of the writing committee said.

FDA clears Impella heart pump to assist in high-risk PCIs

The FDA granted Abiomed premarket approval for its Impella 2.5 heart pump for use during high-risk PCIs. The device provides temporary ventricular support.

TOTAL: Opening eyes but not shutting doors

The major scientific meetings often bill their late-breaking clinical trials as potentially practice-changing revelations. They certainly add insight, even when questions linger.

ACC.15: TOTAL provides clarity for interventional cardiologists

Cardiovascular Business met with Ajay J. Kirtane, MD, SM, from the Center for Interventional Vascular Therapy and chief academic officer at Columbia University Medical Center in New York City, on March 16, the closing day of the American College of Cardiology scientific session. Here is what he offered as highlights.

FDA recalls sheaths used for caths

The FDA issued a class 1 recall on Medtronic’s 10 French FlexCath Select Steerable Sheath, citing problems that may occur with the device outside a patient’s body.

Everolimus-eluting stent outcomes roll snake eyes in registry analysis

Contrary to previous gains with new interventional technology, data suggest that second-generation, everolimus-eluting stents have similar rates of death as CABG. Moreover, PCI with these stents had increased rates of MI and repeat revascularization but a lower rate of stroke. 

ACC.15: TOTAL raises flag over use of routine thrombectomy

TOTAL may not totally spell the end of routine manual thrombectomy with PCI, but it should make interventional cardiologists think twice about using it with STEMI patients. The large, international trial showed no clinical benefit and possible harm.

ACC.15: Do less testing & DAPT’s OK among trial takeaways

Jeffrey Cavendish, MD, of Kaiser Permanente in San Diego, shared his impressions of the first day of the American College of Cardiology’s (ACC) scientific session with Cardiovascular Business. His highlights touch on three Ps: prevention, PROMISE and PEGASUS.

ACC.15: Ticagrelor stays course of low long-term MI, death, stroke rates

Over the long term, therapy that combined ticagrelor and aspirin appeared to maintain a lower rate of recurrent MI, cardiovascular death or stroke in patients with prior MI. Rates of major bleeding, however were higher with the P2Y12 receptor inhibitor over the three-year follow-up.

Culprit or complete? Primary PCI findings add to ongoing stenting debate

British researchers comparing primary PCI revascularization in patients with STEMI and multivessel disease found better outcomes for patients when all lesions were treated as opposed to targeting just the culprits.

Bioresorbable scaffolds, drug-eluting stents equal at 9-month follow-up

In a head-to-head comparison, bioresorbable vascular scaffolds were not inferior to the best performing drug-eluting stents, according to research published online March 3. 

Cardinal Health makes $2B bid for Cordis

Cardinal Health is offering to buy the stent pioneering company Cordis for almost $2 billion, Johnson & Johnson announced.

Younger women, clinicians often dismiss signs of heart attack

Many younger women think they’re too young for a heart attack, and healthcare providers don’t take their initial symptoms seriously enough, researchers concluded after interviewing 30 women hospitalized for acute MI.

Guideline-based therapy may be underutilized following PCI, CABG

Rates of optimal care following PCI or CABG surgery were uncomfortably low, according to a study published online Feb. 24 in Circulation. The analysis revealed that by five years of follow-up, only around a third of patients in either group were receiving guideline-based therapies.